March 6, 2024
(press release)
–
Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo, President: Yasuhiko Saito) plans to make investments to strengthen the pharmaceutical cellulose business. These investments will be implemented in the Naoetsu plant (Joetsu-city, Niigata Pref.). The plan is to double the manufacturing capacity of pharmaceutical excipient “Shin-Etsu AQOAT” (Hypromellose Acetate Succinate) with a completion time of Q2, 2026. The estimated investment is 10 billion JP Yen. Shin-Etsu Chemical’s pharmaceutical excipients are made mainly from plant-derived pulp and are widely used, for example as tablet coating agents due to their recognition as being safe for the human body. “Shin-Etsu AQOAT”, which is used in enteric drugs to control the drug delivery target in the human body, is a patented invention by Shin-Etsu Chemical as an enteric coating agent and is supplied all over the world. In recent years, there has been a focus on its feature of enhancing the solubility of low-dissolving active ingredients, expanding global demand. Shin-Etsu Chemical Co., Ltd. has decided to invest to meet the continuous anticipated increase.
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
